Literature DB >> 325982

Sex hormone binding globulin binding capacity, testosterone, 5alpha-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment.

W Bartsch, H J Horst, H Becker, G Nehse.   

Abstract

Sex hormone binding globulin (SHBG) binding capacity, the concentrations of testosterone (T), of 5alpha-dihydrotestosterone (DHT), of oestradiol-17beta (Oe2), of oestrone (Oe1), of prolactin (hPr) and the percentual specific binding of T to SHBG (%TB) were measured in plasma of patients suffering from prostatic carcinoma and of a control group of similar age. No significant differences in any of the investigated parameters were found between the control group and the carcinoma patients before treatment although 15% of the latter showed distinctly elevated hPr values. Treatment of carcinoma patients with 1) Antiandrogen (cyproterone acetate, Androcur) resulted in a significant decrease of T, Oe2 and SHBG. The DHT/T-ratio increased. n=5. 2) Orchidectomy caused an even more pronounced fall in T, DHT, Oe1 and Oe2 blood levels. SHBG was not altered. DHT/T-ratio increased. n=32. 3) Cyproterone acetate after orchidectomy led to elevated hPr values. n=5. 4) Oestrogen (diethylstiboestrol-diphosphate, Honvan) after orchidectomy increased SHBG and hPr. n=6. 5) Corticosteroid (Prednisone, Decortin) after orchidectomy decreased T and SHBG below the levels found after orchidectomy alone. n=5. 6) Diureticum (Mefruside, Baycaron) (n=5) or 7) a placebo (n=7) did not alter any of the parameters measured. 8) Treatment with HCG (Primogonyl) of patients suffering from oligozoospermia resulted in a significant increase of T, DHT and Oe2. SHBG was not altered. DHT/T-ratio decreased. n=7.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 325982     DOI: 10.1530/acta.0.0850650

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  10 in total

1.  Treatment of advanced prostatic cancer with anti-androgens alone and a combination of anti-androgen with anti-prolactin--a pilot study.

Authors:  E Hoogendijk; H J de Voogt
Journal:  Urol Res       Date:  1986

Review 2.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

3.  Role of the pituitary gland in experimental hormonal induction and prevention of benign prostatic hyperplasia in the dog.

Authors:  M F El Etreby; E Friedreich; S H Hasan; A T Mahrous; K Schwarz; T Senge; U Tunn; F Neumann
Journal:  Cell Tissue Res       Date:  1979       Impact factor: 5.249

4.  Immunocytochemical technique for detection of prolactin (PRL) and growth hormone (GH) in hyperplastic and neoplastic lesions of dog prostate and mammary gland.

Authors:  M F El Etreby; A T Mahrous
Journal:  Histochemistry       Date:  1979

5.  Binding capacity of testosterone-estradiol-binding globulin (TeBG), total and calculated unbound concentrations of testosterone in patients with carcinoma of the prostate treated with orchidectomy or estrogens.

Authors:  J E Damber; B Bergman; R Södergård; R Tomić
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

6.  Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer.

Authors:  G Holub; G Lunglmayr; J Spona
Journal:  Urol Res       Date:  1981

7.  The changes in the binding capacity of testosterone-oestradiol binding globulin (TeBG) following castration and DES-D administration in patients with prostatic carcinoma.

Authors:  T Usui; K Sagami; T Kitano; H Nihira; Y Miyachi
Journal:  Urol Res       Date:  1982

8.  Aromatase activity and bone loss in men.

Authors:  Daniela Merlotti; Luigi Gennari; Konstantinos Stolakis; Ranuccio Nuti
Journal:  J Osteoporos       Date:  2011-06-24

9.  Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study.

Authors:  S O Andersson; H O Adami; R Bergström; L Wide
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

10.  Serum testosterone and dihydrotestosterone in carcinoma of the prostate.

Authors:  R Ghanadian; C M Puah; E P O'Donoghue
Journal:  Br J Cancer       Date:  1979-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.